[HTML][HTML] Small molecules in the treatment of COVID-19

S Lei, X Chen, J Wu, X Duan, K Men - Signal transduction and targeted …, 2022 - nature.com
The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

[HTML][HTML] The magic bullet: Niclosamide

H Jiang, AM Li, J Ye - Frontiers in Oncology, 2022 - frontiersin.org
The term 'magic bullet'is a scientific concept proposed by the German Nobel laureate Paul
Ehrlich in 1907, describing a medicine that could specifically and efficiently target a disease …

[HTML][HTML] Identification of a drug binding pocket in TMEM16F calcium-activated ion channel and lipid scramblase

S Feng, C Puchades, J Ko, H Wu, Y Chen… - Nature …, 2023 - nature.com
The dual functions of TMEM16F as Ca2+-activated ion channel and lipid scramblase raise
intriguing questions regarding their molecular basis. Intrigued by the ability of the FDA …

[HTML][HTML] Inhibition of mucus secretion by niclosamide and benzbromarone in airways and intestine

J Ousingsawat, R Centeio, N Reyne, A McCarron… - Scientific Reports, 2024 - nature.com
Abstract The Ca2+ activated Cl− channel TMEM16A (anoctamin 1; ANO1) is expressed in
secretory epithelial cells of airways and intestine. Previous studies provided evidence for a …

[HTML][HTML] Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro

C Gan, Y Wang, Z Xiang, H Liu, Z Tan, Y Xie… - Journal of Advanced …, 2023 - Elsevier
Introduction Idiopathic pulmonary fibrosis (IPF), a life-threatening interstitial lung disease, is
characterized by excessive activation and proliferation of fibroblasts and epithelial …

[HTML][HTML] Niclosamide, but not ivermectin, inhibits anoctamin 1 and 6 and attenuates inflammation of the respiratory tract

J Ousingsawat, R Centeio, R Schreiber… - … -European Journal of …, 2024 - Springer
Inflammatory airway diseases like cystic fibrosis, asthma and COVID-19 are characterized
by high levels of pulmonary cytokines. Two well-established antiparasitic drugs, niclosamide …

Targeting SARS-CoV-2 and host cell receptor interactions

SP Lim - Antiviral Research, 2023 - Elsevier
Despite the availability of vaccines and therapeutics, continual genetic alterations render the
severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) a persistent threat …

[HTML][HTML] Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

M Rao, E McDuffie, C Sachs - Toxics, 2023 - mdpi.com
The process of discovering small molecule drugs involves screening numerous compounds
and optimizing the most promising ones, both in vitro and in vivo. However, approximately …

[HTML][HTML] Drug repurposing to enhance antitumor response to PD-1/PD-L1 immune checkpoint inhibitors

X Thuru, R Magnez, H El-Bouazzati, G Vergoten… - Cancers, 2022 - mdpi.com
Simple Summary Novel pharmacological approaches are needed to improve treatments of
advanced cancers, despite the considerable benefit of immunotherapy. New drugs are …

[HTML][HTML] Niclosamide as a promising therapeutic player in human cancer and other diseases

Z Wang, J Ren, J Du, H Wang, J Liu… - International Journal of …, 2022 - mdpi.com
Niclosamide is an FDA-approved anthelmintic drug for the treatment of parasitic infections.
However, over the past few years, increasing evidence has shown that niclosamide could …